Asif Talal, Lee Chuy Katherine, Malhotra Saurabh
Division of Cardiology, Cook County Health, Chicago, IL, USA.
Division of Cardiology, Rush Medical College, Chicago, IL, USA.
J Nucl Cardiol. 2021 Oct;28(5):2046-2055. doi: 10.1007/s12350-020-02136-x. Epub 2020 May 27.
Regadenoson, a selective A2A receptor agonist, is widely used for vasodilator stress myocardial perfusion imaging and has a superior adverse effect profile when compared with other agents. However, with widespread use, there have been several reported cases of Regadenoson induced bradyarrhythmias and even asystole in patients with no known conduction system disease. In this article, we report a case of asystole following Regadenoson administration, evaluate mechanisms and risk factors for Regadenoson induced bradyarrhythmias to better identify patients at risk. We also review the available treatment options and propose recommendations for limiting its risk.
雷加曲班是一种选择性A2A受体激动剂，广泛用于血管扩张剂负荷心肌灌注成像，与其他药物相比，其不良反应较少。然而，随着其广泛应用，已有数例报告称，在无已知传导系统疾病的患者中，雷加曲班可诱发缓慢性心律失常，甚至心脏停搏。在本文中，我们报告了1例雷加曲班给药后发生心脏停搏的病例，评估雷加曲班诱发缓慢性心律失常的机制和危险因素，以便更好地识别高危患者。我们还回顾了现有的治疗选择，并提出限制其风险的建议。
